» Articles » PMID: 11967263

Expression and Characterization of GSK-3 Mutants and Their Effect on Beta-catenin Phosphorylation in Intact Cells

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2002 Apr 23
PMID 11967263
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Glycogen synthase kinase-3 (GSK-3) is a serine-threonine kinase that is involved in multiple cellular signaling pathways, including the Wnt signaling cascade where it phosphorylates beta-catenin, thus targeting it for proteasome-mediated degradation. Unlike phosphorylation of glycogen synthase, phosphorylation of beta-catenin by GSK-3 does not require priming in vitro, i.e. it is not dependent on the presence of a phosphoserine, four residues C-terminal to the GSK-3 phosphorylation site. Recently, a means of dissecting GSK-3 activity toward primed and non-primed substrates has been made possible by identification of the R96A mutant of GSK-3beta. This mutant is unable to phosphorylate primed but can still phosphorylate unprimed substrates (Frame, S., Cohen, P., and Biondi R. M. (2001) Mol. Cell 7, 1321-1327). Here we have investigated whether phosphorylation of Ser(33), Ser(37), and Thr(41) in beta-catenin requires priming through prior phosphorylation at Ser(45) in intact cells. We have shown that the Arg(96) mutant does not induce beta-catenin degradation but instead stabilizes beta-catenin, indicating that it is unable to phosphorylate beta-catenin in intact cells. Furthermore, if Ser(45) in beta-catenin is mutated to Ala, beta-catenin is markedly stabilized, and phosphorylation of Ser(33), Ser(37), and Thr(41) in beta-catenin by wild type GSK-3beta is prevented in intact cells. In addition, we have shown that the L128A mutant, which is deficient in phosphorylating Axin in vitro, is still able to phosphorylate beta-catenin in intact cells although it has reduced activity. Mutation of Tyr(216) to Phe markedly reduces the ability of GSK-3beta to phosphorylate and down-regulate beta-catenin. In conclusion, we have found that the Arg(96) mutant has a dominant-negative effect on GSK-3beta-dependent phosphorylation of beta-catenin and that targeting of beta-catenin for degradation requires prior priming through phosphorylation of Ser(45).

Citing Articles

Antimicrobial agent chloroxylenol targets β‑catenin‑mediated Wnt signaling and exerts anticancer activity in colorectal cancer.

Sun Q, Liu B, Lan Q, Su Z, Fu Q, Wang L Int J Oncol. 2023; 63(5).

PMID: 37681484 PMC: 10546378. DOI: 10.3892/ijo.2023.5569.


Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration.

Rippin I, Eldar-Finkelman H Cells. 2021; 10(2).

PMID: 33572709 PMC: 7911291. DOI: 10.3390/cells10020262.


GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer.

Silva-Garcia O, Cortes-Vieyra R, Mendoza-Ambrosio F, Ramirez-Galicia G, Baizabal-Aguirre V Biomolecules. 2020; 10(12).

PMID: 33339170 PMC: 7765659. DOI: 10.3390/biom10121683.


Inhibition of the Wnt Signalling Pathway: An Avenue to Control Breast Cancer Aggressiveness.

Castagnoli L, Tagliabue E, Pupa S Int J Mol Sci. 2020; 21(23).

PMID: 33260642 PMC: 7730964. DOI: 10.3390/ijms21239069.


Casein Kinase 1α as a Regulator of Wnt-Driven Cancer.

Shen C, Nayak A, Melendez R, Wynn D, Jackson J, Lee E Int J Mol Sci. 2020; 21(16).

PMID: 32824859 PMC: 7460588. DOI: 10.3390/ijms21165940.